SAN DIEGO (MedPage Today) -- Progression-free survival in metastatic breast cancer doubled in patients who received a new class of targeted therapy in addition to standard hormonal treatment, a randomized trial showed. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment